EMERGING CAUSES OF DRUG-INDUCED DRY EYE DISEASE A REVIEW OF DRY EYE-ASSOCIATED REPORTS IN THE FDA ADVERSE EVENT REPORTING SYSTEM
Main Article Content
Abstract
Dry Eye Syndrome (DES) is a chronic condition which affects patients of all ages, ethnicities, and sex. The range of symptoms can vary from mild to severe. Much research has been dedicated into better under-standing DES etiology. However, there has been little research into the prevalence of drug-induced or drug-associated DES in patients beyond the typically known candidates such as antihistamines and anti-cholinergics. The aim of this manuscript is to investigate and compare the top 50 systemic and ophthalmic
drug causes for DES noted in the publicly-available FDA Adverse Event Reporting System (FAERS). Investigating the FAERS database, we uncovered several drugs associated with a high incidence of DES development that were not widely known previously, such as Monoclonal Antibodies and Chemotherapy Agents. Among the top 50 drugs associated with DES, 70.46% of reports were from females with 80.65% of reports originating in the US. The median age of individuals reporting was 56. Monoclonal Antibodies were significantly more widely reported compared to other identified drug categories, comprising 26.17% of total reports.
The findings from this study have the potential to inform and raise awareness among clinicians about emerging drug-induced causes of DES.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of articles published in all DPG titles is retained by the author(s). The author(s) grants DPG the rights to publish the article and identify itself as the original publisher. The author grants DPG exclusive commercial rights to the article. The author grants any party the rights to use the article freely for non-commercial purposes provided that the original work is properly cited.
References
1. Messmer EM. The Pathophysiology, Diagnosis, and Treatment of Dry Eye Disease. Dtsch Ärztebl Int. 2015;112(5):71–82. https://doi.org/10.3238/ arztebl.2015.0071
2. Chia EM, Mitchell P, Rochtchina E, Lee AJ, Maroun R, Wang JJ. Prevalence and associations of dry eye syndrome in an older population: the Blue Mountains Eye Study. Clin Experiment Ophthalmol. 2003;31(3):229–232. https://doi. org/10.1046/j.1442-9071.2003.00634.x
3. Common and important ocular surface conditions.
Community Eye Health. 2016;29(95):50–51.
4. Golden MI, Meyer JJ, Zeppieri M, Patel BC.
Dry Eye Syndrome. In: StatPearls. StatPearls Publishing; 2024. Accessed September 22, 2024. http://www.ncbi.nlm.nih.gov/books/NBK470411/
5. Allison K, Morabito KA, Qin H. Improving Compliance with Glaucoma Therapies through the Examination of Environmental Factors and the Localized Side Effects of Glaucoma Drugs. 1(3).
6. Georgoudis P, Sabatino F, Szentmary N, et al. Ocular Mucous Membrane Pemphigoid: Current State of Pathophysiology, Diagnostics and Treatment. Ophthalmol Ther. 2019;8(1):5–17. https://doi.org/10.1007/s40123-019-0164-z
7. Kam KW, Di Zazzo A, De Gregorio C, Narang P, Jhanji V, Basu S. A review on drug-induced dry eye disease. Indian J Ophthalmol. 2023;71(4):1263–1269. https://doi.org/10.4103/IJO.IJO_2782_22
8. Dry eyes: How to maintain clear, comfortable vision-Dry eyes - Symptoms & causes. Mayo Clinic. Accessed October 19, 2024. https://www. mayoclinic.org/diseases-conditions/dry-eyes/ symptoms-causes/syc-20371863
9. Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II Epidemiology Report. Ocul Surf. 2017;15(3): 334–365. https://doi.org/10.1016/j.jtos.2017.05.003
10. Papas EB. The global prevalence of dry eye dis-ease: A Bayesian view. Ophthalmic Physiol Opt J Br Coll Ophthalmic Opt Optom. 2021;41(6):1254– 1266. https://doi.org/10.1111/opo.12888
11. Ophthalmic Drugs Market Size, Share & Trends Report, 2030. Accessed September 22, 2024. https:// www.grandviewresearch.com/industry-analysis/ ophthalmic-therapeutics-drug-market
12. Dry Eye Syndrome Treatment Market Size Report, 2030. Accessed September 22, 2024. https:// www.grandviewresearch.com/industry-analysis/ dry-eye-syndrome-treatment-market
13. Iarikov D, Wassel R, Farley J, Nambiar S. Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database. Infect Dis Ther. 2015;4(4):433–458. https://doi.org/10.1007/ s40121-015-0092-8
14. Yu RJ, Krantz MS, Phillips EJ, Stone CA. Emerging Causes of Drug–Induced Anaphylaxis: A Review of Anaphylaxis–Associated Reports in the FDA Adverse Event Reporting System (FAERS). J Allergy Clin Immunol Pract. 2021;9(2):819–829. e2. https://doi.org/10.1016/j.jaip.2020.09.021
15. FDA Adverse Event Reporting System (FAERS) Public Dashboard. FDA. Published online December 7, 2023. Accessed September 22, 2024. https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard
16. Anatomical Therapeutic Chemical (ATC) Classification. Accessed September 5, 2025. https://www.who.int/tools/atc-ddd-toolkit/ atc-classification
17. Becerra CMC, Ding Y, Kenol B, Hendershot A, Meara AS. Ocular side effects of antirheumatic medications: a qualitative review. BMJ Open Ophthalmol. 2020;5(1). https://doi.org/10.1136/ bmjophth-2019-000331
18. Foley P, Kerdraon YA, Hogden JP, et al. Dupilumab-associated ocular surface disease: An interdisciplinary decision framework for prescrib-ers in the Australian setting. Australas J Dermatol. 2022;63(4):421–436. https://doi.org/10.1111/ajd. 13924
19. Yang Y, Huang C, Lin X, et al. 0.005% Preservative-Free Latanoprost Induces Dry Eye-Like Ocular Surface Damage via Promotion of Inflammation in Mice. Invest Ophthalmol Vis Sci. 2018;59(8): 3375–3384. https://doi.org/10.1167/iovs.18-24013
20. Kothari M, Wanjari A, Acharya S, et al. A Comprehensive Review of Monoclonal Antibodies in Modern Medicine: Tracing the Evolution of a Revolutionary Therapeutic Approach. Cureus. 16(6):e61983. https://doi.org/10.7759/cureus.61983
21. Andreano E, Nicastri E, Paciello I, et al. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients. Cell. 2021;184(7):1821. https://doi.org/10.1016/j.cell.2021.02.035
22. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136(2):318–326. https://doi.org/10.1016/s0002-9394(03)00218-6
23. Matossian C, McDonald M, Donaldson KE, Nichols KK, MacIver S, Gupta PK. Dry Eye Disease: Consideration for Women’s Health. J Womens Health. 2019;28(4):502–514. https://doi. org/10.1089/jwh.2018.7041
24. de Paiva CS. Effects of Aging in Dry Eye. Int Ophthalmol Clin. 2017;57(2):47–64. https://doi. org/10.1097/IIO.0000000000000170
25. Sharma A, Hindman HB. Aging: A Predisposition to Dry Eyes. J Ophthalmol. 2014;2014:781683. https://doi.org/10.1155/2014/781683
26. Gu Q, Dillon CF, Burt VL. Prescription Drug Use Continues to Increase: U.S. Prescription Drug Data for 2007–2008: (665492010-001). Published online 2010. https://doi.org/10.1037/e665492010-001
27. Moss SE, Klein R, Klein BEK. Long-term inci-dence of dry eye in an older population. Optom Vis Sci Off Publ Am Acad Optom. 2008;85(8):668–674. https://doi.org/10.1097/OPX.0b013e318181a947
28. Kinch MS, Kraft Z, Schwartz T. Monoclonal anti-bodies: Trends in therapeutic success and commer-cial focus. Drug Discov Today. 2023;28(1):103415. https://doi.org/10.1016/j.drudis.2022.103415
29. Lu RM, Hwang YC, Liu IJ, et al. Development of therapeutic antibodies for the treatment of diseases. J Biomed Sci. 2020;27(1):1. https://doi.org/10.1186/ s12929-019-0592-z
30. Huang D, Li Z. Multidimensional immunotherapy for dry eye disease: current status and future direc-tions. Front Ophthalmol. 2024;4:1449283. https:// doi.org/10.3389/fopht.2024.1449283